CN| EN

Home  > Clinical services  >  Multi-gene Testing For Hematonosis  > Intended group

    1. Patients who are preliminarily diagnosed with different types of leukemia;

    2. Patients who are preliminarily diagnosed with myelodysplastic syndrome (MDS);

    3. Patients who are preliminarily diagnosed with myeloproliterative neoplasm (MPN);

    4. Patients who are preliminarily diagnosed with myelodysplastic syndrome/myeloproliterative neoplasm (MDS/MPN);

    5. Patients suspected of hematologic neoplasms whose types are not confirmed.

Patients with intractable recurrent diseases can also benefit from the test afterwards:

    1. Detection of the whole mutation hot spots for the purpose of understanding the causes of diseases;

    2. Monitoring sub-clone low-frequency mutations to prevent recurrence or transformation to disease subtypes;

    3. Detection of mutation site for targeted drug resistance.

Copyright2012 Annoroad.com

All rights reserved Annoroad Gene Technology 京ICP备12029022号-1